Here's a piece from Brad Webb, partner at Claremont Creek Ventures, published in Xonomy today. He opines that the recent anti-stem cell ruling (currently being appealed by Obama administration) will have a negative effect on venture capital flowing into stem cell biotechs.
Yesterday, even the NIH shut down its stem cell funding for internal programs while this situation is being sorted out legally. This type of political/regulatory back and forth results in strong investor uncertainty. This is not a good thing for continued investment. It can't help but have a dampening effect.
Posted by Bruce Lehr September 1st 2010.